SEC22A
gene geneOn this page
Summary
SEC22A (SEC22 homolog A, vesicle trafficking protein, HGNC:20260) is a protein-coding gene on chromosome 3q21.1, encoding Vesicle-trafficking protein SEC22a (Q96IW7). May be involved in vesicle transport between the ER and the Golgi complex.
The protein encoded by this gene belongs to the member of the SEC22 family of vesicle trafficking proteins. This protein has similarity to rat SEC22 and may act in the early stages of the secretory pathway.
Source: NCBI Gene 26984 — RefSeq curated summary.
At a glance
- GWAS associations: 1
- Clinical variants (ClinVar): 49 total
- MANE Select transcript:
NM_012430
Identifiers
Gene identifiers
| Field | Value |
|---|---|
| HGNC ID | HGNC:20260 |
| Approved symbol | SEC22A |
| Name | SEC22 homolog A, vesicle trafficking protein |
| Location | 3q21.1 |
| Locus type | gene with protein product |
| Status | Approved |
| Ensembl gene | ENSG00000121542 |
| Ensembl biotype | protein_coding |
| OMIM | 612442 |
| Entrez | 26984 |
Gene structure
Transcript identifiers
Ensembl transcripts: 22 — 20 protein_coding, 1 nonsense_mediated_decay, 1 protein_coding_CDS_not_defined
ENST00000309934, ENST00000466519, ENST00000466950, ENST00000473494, ENST00000477063, ENST00000480631, ENST00000481965, ENST00000487572, ENST00000491366, ENST00000492595, ENST00000908419, ENST00000908421, ENST00000908422, ENST00000908423, ENST00000908424, ENST00000916521, ENST00000916522, ENST00000916523, ENST00000916524, ENST00000916525, ENST00000945893, ENST00000945894
RefSeq mRNA: 1 — MANE Select: NM_012430
NM_012430
CCDS: CCDS3021
Canonical transcript exons
ENST00000492595 — 7 exons
| Exon | Start | End |
|---|---|---|
| ENSE00000823786 | 123245899 | 123246014 |
| ENSE00001938820 | 123271522 | 123274136 |
| ENSE00001943940 | 123201943 | 123201986 |
| ENSE00003493274 | 123259524 | 123259589 |
| ENSE00003501929 | 123225103 | 123225297 |
| ENSE00003553502 | 123209199 | 123209399 |
| ENSE00003640550 | 123223559 | 123223722 |
Expression profiles
Bgee: expression breadth ubiquitous, 249 present calls, max score 92.43.
FANTOM5 (CAGE): breadth ubiquitous, TPM avg 15.3347 / max 143.5361, expressed in 1793 samples.
FANTOM5 promoters (2 alternative TSS)
| Promoter ID | TPM avg | Samples expressed |
|---|---|---|
| 38277 | 14.5983 | 1787 |
| 38278 | 0.7363 | 271 |
Top tissues by expression
278 total, by Bgee expression score (0-100, higher = more expressed):
| Tissue | Anatomy ID | Expression score | Quality |
|---|---|---|---|
| secondary oocyte | CL:0000655 | 92.43 | gold quality |
| oocyte | CL:0000023 | 92.30 | gold quality |
| calcaneal tendon | UBERON:0003701 | 91.81 | gold quality |
| islet of Langerhans | UBERON:0000006 | 89.21 | gold quality |
| primordial germ cell in gonad | CL:0000670 ∩ UBERON:0000991 | 88.94 | gold quality |
| left testis | UBERON:0004533 | 86.21 | gold quality |
| male germ line stem cell (sensu Vertebrata) in testis | CL:0000089 ∩ UBERON:0000473 | 86.14 | gold quality |
| right testis | UBERON:0004534 | 85.85 | gold quality |
| testis | UBERON:0000473 | 85.26 | gold quality |
| ventricular zone | UBERON:0003053 | 84.68 | gold quality |
| adrenal tissue | UBERON:0018303 | 84.63 | gold quality |
| ganglionic eminence | UBERON:0004023 | 84.15 | gold quality |
| stromal cell of endometrium | CL:0002255 | 83.72 | gold quality |
| skin of abdomen | UBERON:0001416 | 83.58 | gold quality |
| skin of leg | UBERON:0001511 | 83.58 | gold quality |
| popliteal artery | UBERON:0002250 | 83.37 | gold quality |
| tibial artery | UBERON:0007610 | 83.36 | gold quality |
| gall bladder | UBERON:0002110 | 83.34 | gold quality |
| rectum | UBERON:0001052 | 83.29 | gold quality |
| pancreas | UBERON:0001264 | 83.08 | gold quality |
| smooth muscle tissue | UBERON:0001135 | 83.00 | gold quality |
| lower esophagus mucosa | UBERON:0035834 | 82.99 | gold quality |
| monocyte | CL:0000576 | 82.97 | gold quality |
| right coronary artery | UBERON:0001625 | 82.74 | gold quality |
| esophagus mucosa | UBERON:0002469 | 82.68 | gold quality |
| aorta | UBERON:0000947 | 82.65 | gold quality |
| leukocyte | CL:0000738 | 82.63 | gold quality |
| descending thoracic aorta | UBERON:0002345 | 82.46 | gold quality |
| mononuclear cell | CL:0000842 | 82.42 | gold quality |
| cortical plate | UBERON:0005343 | 82.22 | gold quality |
Single-cell (SCXA)
Detected in 1 experiment(s), a significant marker in 1.
| Experiment | Marker? | Max mean expression |
|---|---|---|
| E-ANND-3 | yes | 6.37 |
Regulation
Is transcription factor: no
miRNA regulators (miRDB)
123 targeting SEC22A, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):
| miRNA | Max score | Avg score | miRNA target_count |
|---|---|---|---|
| HSA-MIR-5692A | 100.00 | 74.40 | 6850 |
| HSA-MIR-5193 | 100.00 | 67.26 | 1744 |
| HSA-MIR-6740-5P | 100.00 | 65.64 | 932 |
| HSA-MIR-126-5P | 100.00 | 72.71 | 3180 |
| HSA-MIR-4282 | 99.99 | 75.36 | 6408 |
| HSA-MIR-1184 | 99.99 | 68.19 | 1458 |
| HSA-MIR-4531 | 99.99 | 69.70 | 3181 |
| HSA-MIR-196A-1-3P | 99.99 | 72.15 | 2772 |
| HSA-MIR-548P | 99.98 | 72.25 | 3784 |
| HSA-MIR-548N | 99.98 | 71.94 | 4170 |
| HSA-MIR-19A-3P | 99.98 | 75.33 | 2762 |
| HSA-MIR-19B-3P | 99.98 | 75.44 | 2754 |
| HSA-MIR-27A-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-27B-3P | 99.98 | 72.13 | 2955 |
| HSA-MIR-9985 | 99.98 | 72.11 | 2939 |
| HSA-MIR-548AN | 99.97 | 70.91 | 2817 |
| HSA-MIR-607 | 99.97 | 73.62 | 5593 |
| HSA-MIR-128-3P | 99.95 | 71.17 | 2484 |
| HSA-MIR-216A-3P | 99.95 | 71.19 | 2505 |
| HSA-MIR-548AB | 99.95 | 71.31 | 3488 |
| HSA-MIR-559 | 99.95 | 72.28 | 3609 |
| HSA-MIR-651-3P | 99.94 | 73.48 | 5177 |
| HSA-MIR-548A-5P | 99.94 | 71.27 | 3482 |
| HSA-MIR-548AD-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AE-5P | 99.94 | 71.23 | 3502 |
| HSA-MIR-548AK | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AM-5P | 99.94 | 71.24 | 3488 |
| HSA-MIR-548AP-5P | 99.94 | 71.14 | 3489 |
| HSA-MIR-548AQ-5P | 99.94 | 71.34 | 3426 |
| HSA-MIR-548AR-5P | 99.94 | 71.28 | 3515 |
Literature-anchored findings (GeneRIF, showing 1)
- The 200 kDa crystal structure of Sec22 bound to Sec23/24 reveals that the transport signal is a folded epitope rather than a conventional short peptide sequence. (PMID:17499046)
Cross-species orthologs
8 orthologs
| Organism | Symbol | Gene ID |
|---|---|---|
| danio_rerio | sec22a | ENSDARG00000078328 |
| mus_musculus | Sec22a | ENSMUSG00000034473 |
| rattus_norvegicus | Sec22a | ENSRNOG00000043069 |
| drosophila_melanogaster | Syb | FBGN0003660 |
| caenorhabditis_elegans | WBGENE00004898 | |
| caenorhabditis_elegans | WBGENE00004899 | |
| caenorhabditis_elegans | WBGENE00014084 | |
| caenorhabditis_elegans | WBGENE00044062 |
Paralogs (10): VAMP3 (ENSG00000049245), SEC22C (ENSG00000093183), YKT6 (ENSG00000106636), VAMP4 (ENSG00000117533), VAMP8 (ENSG00000118640), VAMP7 (ENSG00000124333), VAMP1 (ENSG00000139190), VAMP5 (ENSG00000168899), VAMP2 (ENSG00000220205), SEC22B (ENSG00000265808)
Protein
Protein identifiers
Vesicle-trafficking protein SEC22a — Q96IW7 (reviewed: Q96IW7)
Alternative names: SEC22 vesicle-trafficking protein homolog A, SEC22 vesicle-trafficking protein-like 2
All UniProt accessions (8): C9J463, C9JDJ8, C9JNZ0, C9JR77, C9JRY4, C9JZ27, F8WAU7, Q96IW7
UniProt curated annotations — full annotation on UniProt →
Function. May be involved in vesicle transport between the ER and the Golgi complex.
Subcellular location. Endoplasmic reticulum membrane.
Similarity. Belongs to the synaptobrevin family.
RefSeq proteins (1): NP_036562* (*=MANE)
Domains & families (InterPro)
| ID | Name | Type |
|---|---|---|
| IPR010908 | Longin_dom | Domain |
| IPR011012 | Longin-like_dom_sf | Homologous_superfamily |
| IPR043546 | Sec22a/c | Family |
| IPR059071 | SEC22a-c_C | Domain |
Pfam: PF13774, PF25970
UniProt features (19 total): topological domain 5, sequence conflict 4, transmembrane region 4, modified residue 3, initiator methionine 1, chain 1, domain 1
Structure
Experimental structures (PDB)
0 structures.
Predicted structure (AlphaFold)
| Model | pLDDT | Fraction very-high |
|---|---|---|
| AF-Q96IW7-F1 | 83.00 | 0.51 |
Functional residue map
Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.
Post-translational modifications (3): 2, 6, 8
Function
Pathways and Gene Ontology
Reactome pathways
8 pathways
| ID | Pathway |
|---|---|
| R-HSA-204005 | COPII-mediated vesicle transport |
| R-HSA-199977 | ER to Golgi Anterograde Transport |
| R-HSA-199991 | Membrane Trafficking |
| R-HSA-392499 | Metabolism of proteins |
| R-HSA-446203 | Asparagine N-linked glycosylation |
| R-HSA-5653656 | Vesicle-mediated transport |
| R-HSA-597592 | Post-translational protein modification |
| R-HSA-948021 | Transport to the Golgi and subsequent modification |
MSigDB gene sets: 97 (showing top):
GOBP_MEMBRANE_FUSION, GOBP_VESICLE_MEDIATED_TRANSPORT, RIZKI_TUMOR_INVASIVENESS_3D_DN, REACTOME_MEMBRANE_TRAFFICKING, GOBP_ENDOPLASMIC_RETICULUM_TO_GOLGI_VESICLE_MEDIATED_TRANSPORT, BLALOCK_ALZHEIMERS_DISEASE_UP, KYNG_DNA_DAMAGE_BY_GAMMA_RADIATION, SPIELMAN_LYMPHOBLAST_EUROPEAN_VS_ASIAN_UP, chr3q21, GOBP_MEMBRANE_ORGANIZATION, GOCC_NUCLEAR_OUTER_MEMBRANE_ENDOPLASMIC_RETICULUM_MEMBRANE_NETWORK, GOCC_ORGANELLE_SUBCOMPARTMENT, GOBP_GOLGI_VESICLE_TRANSPORT, GOMF_SNAP_RECEPTOR_ACTIVITY, REACTOME_POST_TRANSLATIONAL_PROTEIN_MODIFICATION
GO Biological Process (5): endoplasmic reticulum to Golgi vesicle-mediated transport (GO:0006888), protein transport (GO:0015031), retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum (GO:0006890), vesicle-mediated transport (GO:0016192), membrane fusion (GO:0061025)
GO Molecular Function (2): SNAP receptor activity (GO:0005484), protein binding (GO:0005515)
GO Cellular Component (7): endoplasmic reticulum membrane (GO:0005789), cytoplasm (GO:0005737), endoplasmic reticulum (GO:0005783), Golgi apparatus (GO:0005794), endomembrane system (GO:0012505), membrane (GO:0016020), melanosome (GO:0042470)
Reactome top-level categories
Rollup of top-7 pathways:
| Category | Pathways |
|---|---|
| ER to Golgi Anterograde Transport | 1 |
| Membrane Trafficking | 1 |
| Transport to the Golgi and subsequent modification | 1 |
| Vesicle-mediated transport | 1 |
| Post-translational protein modification | 1 |
| Metabolism of proteins | 1 |
| Asparagine N-linked glycosylation | 1 |
GO top-level categories
Rollup of top GO terms by namespace:
| Category | Terms |
|---|---|
| cytoplasm | 3 |
| cellular anatomical structure | 3 |
| Golgi vesicle transport | 2 |
| transport | 2 |
| endomembrane system | 2 |
| intracellular membrane-bounded organelle | 2 |
| intercellular transport | 1 |
| intracellular transport | 1 |
| intracellular protein localization | 1 |
| establishment of protein localization | 1 |
| cellular process | 1 |
| membrane organization | 1 |
| protein-macromolecule adaptor activity | 1 |
| membrane fusion | 1 |
| fusogenic activity | 1 |
| binding | 1 |
| organelle membrane | 1 |
| nuclear outer membrane-endoplasmic reticulum membrane network | 1 |
| endoplasmic reticulum subcompartment | 1 |
| intracellular anatomical structure | 1 |
| vacuole | 1 |
| plasma membrane | 1 |
| pigment granule | 1 |
Protein interactions and networks
STRING
1454 interactions, top by confidence (×1000):
| Protein A | Protein B | Partner UniProt | Score |
|---|---|---|---|
| SEC22A | BET1 | O15155 | 953 |
| SEC22A | GOSR2 | O14653 | 924 |
| SEC22A | STX5 | Q13190 | 877 |
| SEC22A | VTI1B | Q9UEU0 | 846 |
| SEC22A | GOSR1 | O95249 | 696 |
| SEC22A | SCFD1 | Q8WVM8 | 692 |
| SEC22A | BET1L | Q9NYM9 | 691 |
| SEC22A | GORASP2 | Q9H8Y8 | 554 |
| SEC22A | YKT6 | O15498 | 532 |
| SEC22A | GOLGA2 | Q08379 | 522 |
| SEC22A | TRMO | Q9BU70 | 484 |
| SEC22A | ARFIP1 | P53367 | 460 |
| SEC22A | GOLPH3 | Q9H4A6 | 457 |
| SEC22A | TRAPPC5 | Q8IUR0 | 451 |
| SEC22A | TANGO2 | Q6ICL3 | 432 |
IntAct
363 interactions, top by confidence:
| A | B | Type | Score |
|---|---|---|---|
| MSR1 | SEC22A | psi-mi:“MI:0915”(physical association) | 0.780 |
| SEC22A | DTX2 | psi-mi:“MI:0915”(physical association) | 0.780 |
| DTX2 | SEC22A | psi-mi:“MI:0915”(physical association) | 0.780 |
| SEC22A | EDA | psi-mi:“MI:0915”(physical association) | 0.780 |
| TMEM79 | SEC22A | psi-mi:“MI:0915”(physical association) | 0.780 |
| SEC22A | MSR1 | psi-mi:“MI:0915”(physical association) | 0.780 |
| EDA | SEC22A | psi-mi:“MI:0915”(physical association) | 0.780 |
| SEC22A | TMEM79 | psi-mi:“MI:0915”(physical association) | 0.780 |
| SEC22A | ERLIN1 | psi-mi:“MI:0915”(physical association) | 0.720 |
| SFTPC | SEC22A | psi-mi:“MI:0915”(physical association) | 0.720 |
| STX4 | SEC22A | psi-mi:“MI:0915”(physical association) | 0.720 |
| FATE1 | SEC22A | psi-mi:“MI:0915”(physical association) | 0.720 |
| SEC22A | SFTPC | psi-mi:“MI:0915”(physical association) | 0.720 |
| SEC22A | STX4 | psi-mi:“MI:0915”(physical association) | 0.720 |
| SEC22A | FATE1 | psi-mi:“MI:0915”(physical association) | 0.720 |
BioGRID (145): SEC22A (Two-hybrid), SEC22A (Two-hybrid), SEC22A (Two-hybrid), SEC22A (Two-hybrid), SEC22A (Two-hybrid), SEC22A (Two-hybrid), TMEM79 (Two-hybrid), FATE1 (Two-hybrid), DTX2 (Two-hybrid), SYNE4 (Two-hybrid), SEC22A (Affinity Capture-MS), SEC22A (Two-hybrid), SEC22A (Affinity Capture-MS), SEC22A (Affinity Capture-MS), SEC22A (Affinity Capture-MS)
ESM2 similar proteins: A7RVK7, A7TNS4, B4IB36, B4QL99, C0HLF1, C0Z274, C1C4M3, C5DJG1, F4JPP0, O02173, O13732, O43032, O74942, P0C1J0, P12868, P29551, P32613, P32910, P32916, P38247, P38334, P53129, P53237, Q03630, Q03784, Q08972, Q10150, Q21045, Q28HU2, Q29NZ8, Q4R866, Q4S4I5, Q54CA7, Q54DY3, Q54IQ5, Q54ZR7, Q5FV35, Q5ZKP4, Q642F4, Q6FU19
Diamond homologs: O08547, O08595, O75396, P22214, Q4KM74, Q4R866, Q5RAI9, Q5ZJW4, Q642F4, Q6C880, Q6CJA0, Q6FWT0, Q6P7L4, Q74ZD2, Q7SXP0, Q7ZV15, Q8BH47, Q8BXT9, Q94AU2, Q96IW7, Q9BRL7, Q9Y7L0, O70404, Q3T0Y8, Q5REQ5, Q9BV40, Q9WUF4, Q2YDJ2, O60073, P36015, Q6FW27, Q3T000
SIGNOR signaling
0 interactions.
Disease & clinical
Clinical variants and AI predictions
ClinVar
49 variants total. Per-class counts are floors (≥ shown; pagination cap):
| Classification | Count (floor) |
|---|---|
| Pathogenic | 0 |
| Likely pathogenic | 0 |
| Uncertain significance | 34 |
| Likely benign | 2 |
| Benign | 0 |
Top pathogenic / likely-pathogenic (0)
SpliceAI
1266 predictions. Top by Δscore:
| Variant | Effect | Δscore |
|---|---|---|
| 3:123209396:T:G | donor_gain | 1.0000 |
| 3:123209396:T:TG | donor_gain | 1.0000 |
| 3:123209400:G:GG | donor_gain | 1.0000 |
| 3:123223557:A:AG | acceptor_gain | 1.0000 |
| 3:123223558:G:GG | acceptor_gain | 1.0000 |
| 3:123223558:GTTTT:G | acceptor_gain | 1.0000 |
| 3:123223636:T:TA | acceptor_gain | 1.0000 |
| 3:123223637:G:A | acceptor_gain | 1.0000 |
| 3:123223719:TTTGG:T | donor_loss | 1.0000 |
| 3:123223720:TTGGT:T | donor_loss | 1.0000 |
| 3:123223723:G:GT | donor_loss | 1.0000 |
| 3:123223724:T:TC | donor_loss | 1.0000 |
| 3:123225100:T:G | acceptor_gain | 1.0000 |
| 3:123245894:TCCA:T | acceptor_loss | 1.0000 |
| 3:123245895:CCA:C | acceptor_loss | 1.0000 |
| 3:123245896:CAGCT:C | acceptor_loss | 1.0000 |
| 3:123245897:A:AC | acceptor_loss | 1.0000 |
| 3:123245897:A:AG | acceptor_gain | 1.0000 |
| 3:123245898:G:GA | acceptor_gain | 1.0000 |
| 3:123245898:G:GC | acceptor_loss | 1.0000 |
| 3:123259518:TTGCA:T | acceptor_loss | 1.0000 |
| 3:123259519:TGCA:T | acceptor_loss | 1.0000 |
| 3:123259520:GCAGA:G | acceptor_loss | 1.0000 |
| 3:123259521:CAG:C | acceptor_gain | 1.0000 |
| 3:123259521:CAGA:C | acceptor_loss | 1.0000 |
| 3:123259522:A:AG | acceptor_gain | 1.0000 |
| 3:123259522:A:G | acceptor_loss | 1.0000 |
| 3:123259522:AGA:A | acceptor_gain | 1.0000 |
| 3:123259522:AGAGT:A | acceptor_gain | 1.0000 |
| 3:123259523:G:GA | acceptor_gain | 1.0000 |
AlphaMissense
2011 scored. Top likely-pathogenic:
| Variant | Protein change | am_pathogenicity |
|---|---|---|
| 3:123223645:T:C | L90P | 0.999 |
| 3:123209270:T:A | L18H | 0.998 |
| 3:123223632:T:C | F86L | 0.998 |
| 3:123223634:C:A | F86L | 0.998 |
| 3:123223634:C:G | F86L | 0.998 |
| 3:123223656:T:C | F94L | 0.998 |
| 3:123223657:T:C | F94S | 0.998 |
| 3:123223658:C:A | F94L | 0.998 |
| 3:123223658:C:G | F94L | 0.998 |
| 3:123223719:T:C | F115L | 0.998 |
| 3:123223721:T:A | F115L | 0.998 |
| 3:123223721:T:G | F115L | 0.998 |
| 3:123209243:T:A | V9D | 0.997 |
| 3:123209264:T:C | L16P | 0.997 |
| 3:123223581:A:C | S69R | 0.997 |
| 3:123223583:C:A | S69R | 0.997 |
| 3:123223583:C:G | S69R | 0.997 |
| 3:123223626:T:C | F84L | 0.997 |
| 3:123223628:C:A | F84L | 0.997 |
| 3:123223628:C:G | F84L | 0.997 |
| 3:123223636:T:C | L87P | 0.997 |
| 3:123223633:T:C | F86S | 0.996 |
| 3:123225125:G:C | K123N | 0.996 |
| 3:123225125:G:T | K123N | 0.996 |
| 3:123225132:T:G | Y126D | 0.996 |
| 3:123209248:C:A | R11S | 0.995 |
| 3:123209249:G:C | R11P | 0.995 |
| 3:123209270:T:C | L18P | 0.995 |
| 3:123245985:G:C | G210R | 0.995 |
| 3:123223624:C:A | A83D | 0.994 |
dbSNP variants (sampled 300 via entrez): RS1000079850 (3:123219489 A>G), RS1000109860 (3:123235473 C>G), RS1000131704 (3:123248321 A>G), RS1000167391 (3:123223278 C>T), RS1000212545 (3:123237272 A>G), RS1000255878 (3:123240834 C>T), RS1000280029 (3:123274502 A>G), RS1000306871 (3:123229494 CAAAGT>C), RS1000328377 (3:123261211 G>A), RS1000347648 (3:123234820 C>T), RS1000355543 (3:123228158 A>G), RS1000362726 (3:123242018 T>A,C,G), RS1000377389 (3:123273329 A>G), RS1000397332 (3:123248540 T>C), RS1000405058 (3:123216349 G>A)
Disease associations
OMIM: gene MIM:612442 | disease phenotypes:
GenCC curated gene-disease
Mondo (0):
Orphanet (0):
HPO phenotypes
0 total (0 of 0 shown, HPO-id order):
GWAS associations
1 associations (top):
| Study | Trait | p-value |
|---|---|---|
| GCST004899_9 | Gestational age at birth (maternal effect) | 4.000000e-08 |
EFO canonical traits (2, from GWAS)
| EFO ID | Trait name |
|---|---|
| EFO:0005112 | gestational age |
| EFO:0005939 | parental genotype effect measurement |
Drugs & pharmacology
Drug and pharmacology data
Is drug target: no
PharmGKB: 1 entry (VIP=true, CPIC=false)
CTD chemical–gene interactions
23 total (human), top 23 by PubMed support.
| Chemical | Actions (top 5) | PubMed papers |
|---|---|---|
| bisphenol A | decreases expression, increases methylation | 3 |
| Valproic Acid | affects expression, decreases methylation, increases expression | 3 |
| Cisplatin | affects expression, increases expression | 2 |
| Particulate Matter | decreases expression, increases abundance, increases expression | 2 |
| TAK-243 | decreases sumoylation | 1 |
| dicrotophos | decreases expression | 1 |
| methylmercuric chloride | decreases expression | 1 |
| trichostatin A | increases expression | 1 |
| potassium chromate(VI) | affects cotreatment, decreases expression | 1 |
| epigallocatechin gallate | affects cotreatment, decreases expression | 1 |
| di-n-butylphosphoric acid | affects expression | 1 |
| Temozolomide | decreases expression | 1 |
| Decitabine | affects expression | 1 |
| Acetaminophen | increases expression | 1 |
| Air Pollutants | decreases expression, increases abundance | 1 |
| Ethyl Methanesulfonate | increases expression | 1 |
| Formaldehyde | increases expression | 1 |
| Gallic Acid | increases expression | 1 |
| Hydrogen Peroxide | increases expression | 1 |
| Methyl Methanesulfonate | increases expression | 1 |
| Quercetin | decreases expression | 1 |
| Antirheumatic Agents | increases expression | 1 |
| Copper Sulfate | decreases expression | 1 |
Cellosaurus cell lines
3 cell lines: 3 cancer cell line
First 10 cell lines (id-ordered, not curated):
| Cellosaurus | Name | Category | Sex |
|---|---|---|---|
| CVCL_TK31 | HAP1 SEC22A (-) 1 | Cancer cell line | Male |
| CVCL_TK32 | HAP1 SEC22A (-) 2 | Cancer cell line | Male |
| CVCL_TK33 | HAP1 SEC22A (-) 3 | Cancer cell line | Male |
Clinical trials (associated diseases)
0 trials via MONDO — disease-level, not drug-specific.
Related Atlas pages
No linked Atlas pages yet — the cross-entity mesh grows as the corpus expands.